

CITATION REPORT

List of articles citing

100 years of Lewy pathology

DOI: 10.1038/nrneurol.2012.242

Nature Reviews Neurology, 2013, 9, 13-24.

Source: <https://exaly.com/paper-pdf/55452299/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
839	Parkinson's disease dementia: convergence of β -synuclein, tau and amyloid- β pathologies. 2013 , 14, 626-36		495
838	Advances in the genetics of Parkinson disease. <i>Nature Reviews Neurology</i> , 2013 , 9, 445-54	15	353
837	New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. 2013 , 12, 811-21		124
836	Could dysregulation of UPS be a common underlying mechanism for cancer and neurodegeneration? Lessons from UCHL1. 2013 , 67, 45-53		36
835	Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. 2013 , 501, 45-51		1033
834	SUMO and Parkinson's disease. 2013 , 15, 737-59		36
833	The remarkable conformational plasticity of alpha-synuclein: blessing or curse?. 2013 , 19, 368-77		67
832	Acetyltransferases (HATs) as targets for neurological therapeutics. 2013 , 10, 568-88		62
831	Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. 2013 , 3, 1-11		67
830	The function of β -synuclein. 2013 , 79, 1044-66		475
829	Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. 2013 , 125, 491-511		102
828	Parallel PARKing: Parkinson's genes function in common pathway. 2013 , 77, 377-9		3
827	Dementia with Lewy bodies: a common condition in nursing homes?. 2013 , 14, 713-4		3
826	LRRKing up the right trees? On figuring out the effects of mutant LRRK2 and other Parkinson's disease-related genes. 2013 , 3, 73-76		1
825	Amurensin G induces autophagy and attenuates cellular toxicities in a rotenone model of Parkinson's disease. 2013 , 433, 121-6		22
824	Developing therapeutic antibodies for neurodegenerative disease. 2013 , 10, 459-72		128
823	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. 2013 , 12, 514-24		108

822	Tau pathology and neurodegeneration. 2013 , 12, 609-22	698
821	Distinct β -synuclein strains differentially promote tau inclusions in neurons. 2013 , 154, 103-17	476
820	Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers. 2013 , 41, 1103-30	257
819	Demenz mit Lewy-K β ern. 2013 , 7, 337-348	
818	Structure of the human Parkin ligase domain in an autoinhibited state. 2013 , 32, 2099-112	228
817	Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration. 2013 , 3, 415-59	58
816	The pallidopyramidal syndromes: nosology, aetiology and pathogenesis. 2013 , 26, 381-94	22
815	NMR Metabolomics Analysis of Parkinson's Disease. 2013 , 1, 191-209	25
814	Effects of baseline CSF β -synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease. 2013 , 8, e85443	11
813	Sirtuins in neurodegenerative diseases: an update on potential mechanisms. 2013 , 5, 53	86
812	Neuroplasticity and the next wave of antidepressant strategies. 2013 , 7, 218	57
811	Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart. 2014 , 9, e101763	20
810	Lysosomes and β -synuclein form a dangerous duet leading to neuronal cell death. 2014 , 8, 83	53
809	Bioinorganic chemistry of synucleinopathies: deciphering the binding features of Met motifs and His-50 in AS-Cu(I) interactions. 2014 , 141, 208-211	18
808	Gastric dysregulation induced by microinjection of 6-OHDA in the substantia nigra pars compacta of rats is determined by alterations in the brain-gut axis. 2014 , 307, G1013-23	36
807	Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. 2014 , 10, e1004741	127
806	Parkinson's Disease: An Overview of Etiology, Clinical Manifestations, and Treatment. 2014 , 1-24	
805	Is brain copper deficiency in Alzheimer's, Lewy body, and Creutzfeldt Jakob diseases the common key for a free radical mechanism and oxidative stress-induced damage?. 2015 , 43, 1149-56	14

804	Small molecule-mediated stabilization of vesicle-associated helical β -synuclein inhibits pathogenic misfolding and aggregation. 2014 , 5, 5857	75
803	The regulation of catalase activity by PPAR α s affected by β -synuclein. 2014 , 1, 145-59	20
802	Genetics and genomics of Parkinson's disease. 2014 , 6, 48	125
801	Mechanisms of body weight fluctuations in Parkinson's disease. 2014 , 5, 84	61
800	Interactions between calcium and alpha-synuclein in neurodegeneration. 2014 , 4, 795-811	49
799	The potential of light therapy in Parkinson's disease. 2014 , 1	3
798	Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological β -synuclein by enhanced ELISA. 2014 , 2, 29	42
797	Sequence and membrane determinants of the random coil-helix transition of β -synuclein. 2014 , 426, 2130-44	25
796	Immunohistochemical localization of apoptosome-related proteins in Lewy bodies in Parkinson's disease and dementia with Lewy bodies. 2014 , 1571, 39-48	10
795	Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism. 2014 , 35, 1125-31	64
794	Recent advances in Parkinson's disease genetics. 2014 , 261, 259-66	58
793	Genetics of Parkinson's disease--state of the art, 2013. 2014 , 20 Suppl 1, S23-8	156
792	The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of β -synuclein, and enhances its secretion and nuclear localization in cells. 2014 , 23, 4491-509	153
791	Disentangling the molecular genetic basis of personality: from monoamines to neuropeptides. 2014 , 43, 228-39	70
790	Anti-amyloid compounds inhibit β -synuclein aggregation induced by protein misfolding cyclic amplification (PMCA). 2014 , 289, 11897-11905	62
789	The gut-brain axis rewired: adding a functional vagal nicotinic "sensory synapse". 2014 , 28, 3064-74	61
788	A mitocentric view of Parkinson's disease. 2014 , 37, 137-59	86
787	Animal models of Parkinson's disease: a gateway to therapeutics?. 2014 , 11, 92-110	67

786	Hyposmia: a possible biomarker of Parkinson's disease. 2014 , 30, 134-40		31
785	Role of iron in UPS impairment model of Parkinson's disease. 2014 , 20 Suppl 1, S158-61		27
784	Lewy body extracts from Parkinson disease brains trigger β synuclein pathology and neurodegeneration in mice and monkeys. 2014 , 75, 351-62		427
783	Mutant β synuclein enhances firing frequencies in dopamine substantia nigra neurons by oxidative impairment of A-type potassium channels. 2014 , 34, 13586-99		80
782	Modulation of alpha-synuclein toxicity in yeast using a novel microfluidic-based gradient generator. 2014 , 14, 3949-57		25
781	Maternal immune activation and abnormal brain development across CNS disorders. <i>Nature Reviews Neurology</i> , 2014 , 10, 643-60	15	488
780	Human proteins with target sites of multiple post-translational modification types are more prone to be involved in disease. 2014 , 13, 2735-48		26
779	Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. 2014 , 14, 495		85
778	DUBs counteract parkin for efficient mitophagy. 2014 , 33, 2442-3		10
777	Defined β synuclein prion-like molecular assemblies spreading in cell culture. 2014 , 15, 69		58
776	Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells. 2014 , 5, 782-6		27
775	Arylsulphatase A activity in familial parkinsonism: a pathogenetic role?. 2014 , 261, 1803-9		7
774	Cellular maintenance of nuclear protein homeostasis. 2014 , 71, 1865-79		18
773	Residue histidine 50 plays a key role in protecting β synuclein from aggregation at physiological pH. 2014 , 289, 15474-81		17
772	Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs). 2014 , 114, 6661-714		301
771	Selective increase of in vivo firing frequencies in DA SN neurons after proteasome inhibition in the ventral midbrain. 2014 , 40, 2898-909		20
770	Inflammation in Parkinson's Disease. 2014 ,		3
769	The presence of an air-water interface affects formation and elongation of β synuclein fibrils. 2014 , 136, 2866-75		175

768	Parkinson disease subtypes. 2014 , 71, 499-504	310
767	p53 in neurodegenerative diseases and brain cancers. 2014 , 142, 99-113	64
766	Site-specific copper-catalyzed oxidation of β -synuclein: tightening the link between metal binding and protein oxidative damage in Parkinson's disease. 2014 , 53, 4350-8	55
765	Mutant huntingtin is present in neuronal grafts in Huntington disease patients. 2014 , 76, 31-42	130
764	Using (^{19}F) NMR to probe biological interactions of proteins and peptides. 2014 , 9, 1242-50	125
763	Parkinson's disease: animal models and dopaminergic cell vulnerability. 2014 , 8, 155	282
762	Age-Related Changes of 14-3-3 Isoforms in Midbrain of A53T-SNCA Overexpressing Mice. 2015 , 5, 595-604	5
761	Disruption of the autoinhibited state primes the E3 ligase parkin for activation and catalysis. 2015 , 34, 2506-21	119
760	Total and Proteinase K-Resistant β -Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson's Disease. 2015 , 5, 11120	31
759	Detection of Disease-associated β -Synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated β -Synuclein. 2015 , e52752	2
758	Cognitieve stoornissen en dementie bij de ziekte van Parkinson. 2015 , 3, 4-13	
757	Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an β -Synuclein Transgenic Model of Parkinson's Disease. 2015 , 9, 131-40	4
756	β -Synuclein and Lewy pathology in Parkinson's disease. 2015 , 28, 375-81	63
755	Oxidative stress and Parkinson's disease. 2015 , 9, 91	449
754	Inflammation in Parkinson's disease: role of glucocorticoids. 2015 , 9, 32	91
753	Disease-modifying therapeutic directions for Lewy-Body dementias. 2015 , 9, 293	17
752	Network structure of brain atrophy in de novo Parkinson's disease. 2015 , 4,	112
751	Targeting β -Synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. 2015 , 14, 855-866	286

750	Complexin-1 and Foxp1 Expression Changes Are Novel Brain Effects of Alpha-Synuclein Pathology. 2015 , 52, 57-63	16
749	Abnormal thermography in Parkinson's disease. 2015 , 21, 852-7	15
748	GDNF-Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson disease. 2015 , 589, 3760-72	69
747	A novel link between the conformations, exposure of specific epitopes, and subcellular localization of β synuclein. 2015 , 1850, 2497-505	9
746	When rejuvenation is a problem: challenges of modeling late-onset neurodegenerative disease. 2015 , 142, 3085-9	31
745	The connectomics of brain disorders. 2015 , 16, 159-72	882
744	Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle. 2015 , 125, 47-62	50
743	Computational model of visual hallucination in dementia with Lewy bodies. 2015 , 62, 73-82	4
742	Formaldehyde-fixed brain tissue from spontaneously ill β synuclein transgenic mice induces fatal β synucleinopathy in transgenic hosts. 2015 , 129, 157-9	30
741	Spreading of pathology in neurodegenerative diseases: a focus on human studies. 2015 , 16, 109-20	484
740	NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled A β tau, and β synuclein. 2015 , 349, 1255555	564
739	Proteomics Approach to Identify Biomarkers in Neurodegenerative Diseases. 2015 , 121, 59-86	5
738	Fibril growth and seeding capacity play key roles in β synuclein-mediated apoptotic cell death. 2015 , 22, 2107-22	65
737	β synuclein interactions with phospholipid model membranes: Key roles for electrostatic interactions and lipid-bilayer structure. 2015 , 1848, 2002-12	33
736	Parkin Is Dispensable for Mitochondrial Function, but Its Ubiquitin Ligase Activity Is Critical for Macroautophagy and Neurotransmitters: Therapeutic Potential beyond Parkinson's Disease. 2015 , 15, 259-70	10
735	Ubiquitination of the Dishevelled DIX domain blocks its head-to-tail polymerization. 2015 , 6, 6718	46
734	Parkinson's disease. 2015 , 386, 896-912	2652
733	Direct Detection of β synuclein Dimerization Dynamics: Single-Molecule Fluorescence Analysis. 2015 , 108, 2038-47	36

732	Toward stem cell-based phenotypic screens for neurodegenerative diseases. <i>Nature Reviews Neurology</i> , 2015 , 11, 339-50	15	55
731	The anti-hypertensive drug reserpine induces neuronal cell death through inhibition of autophagic flux. 2015 , 462, 402-8		15
730	Copper binding to the N-terminally acetylated, naturally occurring form of alpha-synuclein induces local helical folding. 2015 , 137, 6444-7		52
729	Neurodegenerative diseases: expanding the prion concept. 2015 , 38, 87-103		221
728	Neuroimaging of Parkinson's disease: Expanding views. 2015 , 59, 16-52		89
727	Quantitative detection of dopamine, serotonin and their metabolites in rat model of Parkinson's disease using HPLC-MS/MS. 2015 ,		2
726	Bent out of shape: β synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease. 2015 , 589, 3749-59		41
725	Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors. <i>Nature Reviews Neurology</i> , 2015 , 11, 625-36	15	335
724	Surviving protein quality control catastrophes--from cells to organisms. 2015 , 128, 3861-9		43
723	Resting-state functional magnetic resonance imaging of the subthalamic microlesion and stimulation effects in Parkinson's disease: Indications of a principal role of the brainstem. 2015 , 9, 264-74		35
722	Differential submitochondrial localization of PINK1 as a molecular switch for mediating distinct mitochondrial signaling pathways. 2015 , 27, 2543-54		22
721	Drosophila as an In Vivo Model for Human Neurodegenerative Disease. 2015 , 201, 377-402		172
720	Lack of Neuronal IFN- β FNAR Causes Lewy Body- and Parkinson's Disease-like Dementia. 2015 , 163, 324-39		113
719	Control of protein orientation on gold nanoparticles. 2015 , 119, 21035-21043		59
718	Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease. 2015 , 14, 1054-64		45
717	Structure of the toxic core of β synuclein from invisible crystals. 2015 , 525, 486-90		393
716	Parkinson's disease: Crystals of a toxic core. 2015 , 525, 458-9		5
715	Parkinson Disease and Other Synucleinopathies. 2015 , 281-302		3

714	Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils. 2015 , 74, 89-101	67
713	Role of Inflammation in Neurodegenerative Diseases. 2015 , 380-395	2
712	Invited review: Prion-like transmission and spreading of tau pathology. 2015 , 41, 47-58	100
711	βSynuclein staging in the amygdala of a Parkinson's disease model: cell types involved. 2015 , 41, 137-46	7
710	Historical review of academic concepts of dementia in the world and Japan: with a short history of representative diseases. 2015 , 21, 369-76	1
709	Spreading of βsynuclein in the face of axonal transport deficits in Parkinson's disease: a speculative synthesis. 2015 , 77, 276-83	43
708	Parkinson's Disease (Pathogenesis and Its Management): An Overview. 2016 , 06,	
707	Reconfiguring the Parkinson's Personality in the Twentieth and Twenty-First Centuries. 2016 , 33, 465-492	1
706	Animal Models of Parkinson's Disease. 2016 ,	7
705	Structural Imaging and Parkinson's Disease: Moving Toward Quantitative Markers of Disease Progression. 2016 , 6, 557-67	22
704	Nanomaterials for Neurology: State-of-the-Art. 2016 , 15, 1306-1324	9
703	A Novel Microfluidic Cell Co-culture Platform for the Study of the Molecular Mechanisms of Parkinson's Disease and Other Synucleinopathies. 2016 , 10, 511	31
702	Calcium: Alpha-Synuclein Interactions in Alpha-Synucleinopathies. 2016 , 10, 570	20
701	Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic Mice. 2016 , 17,	40
700	Lmx1a and Lmx1b regulate mitochondrial functions and survival of adult midbrain dopaminergic neurons. 2016 , 113, E4387-96	39
699	Alpha-synuclein propagation: New insights from animal models. 2016 , 31, 161-8	79
698	Combination therapies: The next logical Step for the treatment of synucleinopathies?. 2016 , 31, 225-34	39
697	Resveratrol alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of βsynuclein via SIRT1-deacetylated LC3. 2016 , 60, 2161-2175	94

696	FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF. 2016 , 291, 20811-21	51
695	Nanomolar oligomerization and selective co-aggregation of β synuclein pathogenic mutants revealed by single-molecule fluorescence. 2016 , 6, 37630	24
694	Structural basis of synaptic vesicle assembly promoted by β synuclein. 2016 , 7, 12563	139
693	Leucine-rich repeat kinase 2 (LRRK2) regulates β synuclein clearance in microglia. 2016 , 17, 77	37
692	Structural Ensembles of Membrane-bound β synuclein Reveal the Molecular Determinants of Synaptic Vesicle Affinity. 2016 , 6, 27125	62
691	Virtual reality systems in the rehabilitation of Parkinson's disease. 2016 ,	5
690	Characterization of β synuclein Multimer Stoichiometry in Complex Biological Samples by Electrophoresis. 2016 , 88, 4071-84	9
689	Vagal neurocircuitry and its influence on gastric motility. 2016 , 13, 389-401	135
688	Characterising brain network topologies: A dynamic analysis approach using heat kernels. 2016 , 141, 490-501	19
687	Ret is essential to mediate GDNF's neuroprotective and neuroregenerative effect in a Parkinson disease mouse model. 2016 , 7, e2359	43
686	Pathological β synuclein transmission initiated by binding lymphocyte-activation gene 3. 2016 , 353,	364
685	Activated caspase-9 immunoreactivity in glial and neuronal cytoplasmic inclusions in multiple system atrophy. 2016 , 628, 207-12	11
684	Parkinson's disease: Autoimmunity and neuroinflammation. 2016 , 15, 1005-11	173
683	Distribution and Load of Amyloid- β Pathology in Parkinson Disease and Dementia with Lewy Bodies. 2016 , 75, 936-945	73
682	The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease. 2016 , 137, 331-59	124
681	Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease. 2016 , 139 Suppl 1, 156-178	85
680	Review: Sporadic Parkinson's disease: development and distribution of β synuclein pathology. 2016 , 42, 33-50	232
679	Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. 2016 , 3, 812-818	249

678	Connectivity Changes in Parkinson's Disease. 2016 , 16, 91	33
677	Current and experimental treatments of Parkinson disease: A guide for neuroscientists. 2016 , 139 Suppl 1, 325-337	196
676	Potential Pathways of Abnormal Tau and β Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases. 2016 , 8,	77
675	The effect of yeast <i>Saccharomyces cerevisiae</i> red pigment on the expression of cloned human β Synuclein. 2016 , 10, 264-276	1
674	Neuropsychiatry. 2016 , 905-918	
673	Parkinson's Disease-Associated Mutations Affect Mitochondrial Function. 2016 , 139-158	1
672	Total β Synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA. 2016 , 408, 7669-7677	14
671	Three men in a (same) boat: Alzheimer, Pick, Lewy. Historical notes. 2016 , 7, 526-530	8
670	Interactions Between β Synuclein and Tau Protein: Implications to Neurodegenerative Disorders. 2016 , 60, 298-304	18
669	Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease. 2016 ,	6
668	Neuroprotective Effect of <i>Coptis chinensis</i> in MPP[Formula: see text] and MPTP-Induced Parkinson's Disease Models. 2016 , 44, 907-25	21
667	Trifluoroethanol modulates β Synuclein amyloid-like aggregate formation, stability and dissolution. 2016 , 216, 23-30	6
666	The rs3756063 polymorphism is associated with SNCA methylation in the Chinese Han population. 2016 , 367, 11-4	13
665	Defects in trafficking bridge Parkinson's disease pathology and genetics. 2016 , 539, 207-216	271
664	Lipids and Their Trafficking: An Integral Part of Cellular Organization. 2016 , 39, 139-153	90
663	Novel antibodies to phosphorylated β Synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes. 2016 , 4, 80	33
662	Cutaneous malignant melanoma and Parkinson disease: Common pathways?. 2016 , 80, 811-820	25
661	Site-specific structural dynamics of β Synuclein revealed by time-resolved fluorescence spectroscopy: a review. 2016 , 4, 042002	9

660	A Mathematical Model for the Proliferation, Accumulation and Spread of Pathogenic Proteins Along Neuronal Pathways with Locally Anomalous Trapping. 2016 , 11, 142-156	2
659	Transcription factor Pitx3 mutant mice as a model for Parkinson's disease. 2016 , 11, 427-438	4
658	The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation. 2016 , 4, 128	23
657	Severe Brain Metabolic Decreases Associated with REM Sleep Behavior Disorder in Dementia with Lewy Bodies. 2016 , 52, 989-97	11
656	Targeting β synuclein: Therapeutic options. 2016 , 31, 882-8	33
655	Hippocampal β synuclein and interneurons in Parkinson's disease: Data from human and mouse models. 2016 , 31, 979-88	20
654	Identification of TMEM230 mutations in familial Parkinson's disease. 2016 , 48, 733-9	122
653	The PINK1, synphilin-1 and SIAH-1 complex constitutes a novel mitophagy pathway. 2016 , 25, 3476-3490	70
652	Atomoxetine restores the response inhibition network in Parkinson's disease. 2016 , 139, 2235-48	57
651	Cortical Lewy bodies and α burden are associated with prevalence and timing of dementia in Lewy body diseases. 2016 , 42, 436-50	49
650	Ubiquitin phosphorylation in Parkinson's disease: Implications for pathogenesis and treatment. 2016 , 5, 1	21
649	Structural disorder of monomeric β synuclein persists in mammalian cells. 2016 , 530, 45-50	534
648	Intracellular repair of oxidation-damaged β synuclein fails to target C-terminal modification sites. 2016 , 7, 10251	65
647	Targeting intrinsically disordered proteins in rational drug discovery. 2016 , 11, 65-77	51
646	Conformational Compatibility Is Essential for Heterologous Aggregation of β synuclein. 2016 , 7, 719-27	19
645	β -Synuclein strains and the variable pathologies of synucleinopathies. 2016 , 139 Suppl 1, 256-274	58
644	Co-expression of truncated and full-length tau induces severe neurotoxicity. 2016 , 21, 1790-1798	32
643	Neurological Diseases from a Systems Medicine Point of View. 2016 , 1386, 221-50	3

642	Lysines, Achilles' heel in alpha-synuclein conversion to a deadly neuronal endotoxin. 2016 , 26, 62-71	24
641	Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. 2016 , 131, 49-73	125
640	Current disease modifying approaches to treat Parkinson's disease. 2016 , 73, 1365-79	78
639	Neuroregeneration: Disease Modeling and Therapeutic Strategies for Alzheimer's and Parkinson's Diseases. 2016 , 293-325	1
638	Dopaminergic lesioning impairs adult hippocampal neurogenesis by distinct modification of β -synuclein. 2016 , 94, 62-73	21
637	Biomedical Engineering: Frontier Research and Converging Technologies. 2016 ,	
636	Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. 2017 , 155, 171-193	89
635	Metabolic connectomics targeting brain pathology in dementia with Lewy bodies. 2017 , 37, 1311-1325	39
634	Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease. 2017 , 155, 76-95	78
633	Circadian rhythm dysfunction: a novel environmental risk factor for Parkinson's disease. 2017 , 22, 280-286	54
632	Selective neuronal vulnerability in Parkinson disease. 2017 , 18, 101-113	465
631	Blood RNA biomarkers in prodromal PARK4 and rapid eye movement sleep behavior disorder show role of complexin 1 loss for risk of Parkinson's disease. 2017 , 10, 619-631	15
630	Evidence for Intramolecular Antiparallel Beta-Sheet Structure in Alpha-Synuclein Fibrils from a Combination of Two-Dimensional Infrared Spectroscopy and Atomic Force Microscopy. 2017 , 7, 41051	82
629	In Situ Peroxidase Labeling and Mass-Spectrometry Connects Alpha-Synuclein Directly to Endocytic Trafficking and mRNA Metabolism in Neurons. 2017 , 4, 242-250.e4	61
628	LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis. 2017 , 45, 113-122	34
627	Role of the microtubule-associated TPPP/p25 in Parkinson's and related diseases and its therapeutic potential. 2017 , 14, 301-309	13
626	Opicapone for the treatment of Parkinson's disease. 2017 , 18, 445-453	11
625	Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity. 2017 , 60, 2983-2992	81

624	Towards understanding cellular structure biology: In-cell NMR. 2017 , 1865, 547-557	16
623	Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases. 2017 , 131, 1-15	29
622	Biological Basis for Amyloidogenesis in Alzheimer's Disease. 2017 , 82, 122-139	19
621	Neuroprotective Effect of Ayurvedic Preparations and Natural Products on Parkinson's Disease. 2017 , 91-105	2
620	Clinical Features and Differential Diagnosis of Parkinson's Disease. 2017 , 103-115	2
619	Disease progression in LRRK2 parkinsonism. 2017 , 16, 334-335	1
618	Historical landmarks in dementia with Lewy bodies. 2017 , 16, 348	1
617	Drift diffusion model of reward and punishment learning in rare alpha-synuclein gene carriers. 2017 , 31, 17-22	2
616	Decreased baroreflex sensitivity in Parkinson's disease is associated with orthostatic hypotension. 2017 , 377, 207-211	18
615	Ubiquitin and Parkinson's disease through the looking glass of genetics. 2017 , 474, 1439-1451	36
614	Raman optical activity of human α -synuclein in intrinsically disordered, micelle-bound α -helical, molten globule and oligomeric β -sheet state. 2017 , 48, 910-918	25
613	References. 2017 , 301-354	
612	Changes in the oxidative stress/anti-oxidant system after exposure to sulfur mustard and antioxidant strategies in the therapy, a review. 2017 , 27, 408-416	9
611	α -Synuclein promotes dilation of the exocytotic fusion pore. 2017 , 20, 681-689	149
610	Copper increases the ability of 6-hydroxydopamine to generate oxidative stress and the ability of ascorbate and glutathione to potentiate this effect: potential implications in Parkinson's disease. 2017 , 141, 738-749	16
609	The Transcellular Propagation and Intracellular Trafficking of α -Synuclein. 2017 , 7,	19
608	Brain-to-stomach transfer of α -Synuclein via vagal preganglionic projections. 2017 , 133, 381-393	118
607	Distinct cellular and molecular environments support aging-related DNA methylation changes in the substantia nigra. 2017 , 9, 21-31	14

606	Anti-Parkinsonian effects of ßmyrin are regulated via LGG-1 involved autophagy pathway in <i>Caenorhabditis elegans</i> . 2017 , 36, 118-125	30
605	A Nigro-Vagal Pathway Controls Gastric Motility and Is Affected in a Rat Model of Parkinsonism. 2017 , 153, 1581-1593	60
604	Prion-like transmission of ßsynuclein pathology in the context of an NFL null background. 2017 , 661, 114-120	2
603	Randomized CRISPR-Cas Transcriptional Perturbation Screening Reveals Protective Genes against Alpha-Synuclein Toxicity. 2017 , 68, 247-257.e5	24
602	Propagation of Misfolded Proteins in Neurodegeneration: Insights and Cautions from the Study of Prion Disease Prototypes. 2017 , 203-223	
601	FACS-Assisted CRISPR-Cas9 Genome Editing Facilitates Parkinson's Disease Modeling. 2017 , 9, 1423-1431	49
600	Prying into the Prion Hypothesis for Parkinson's Disease. 2017 , 37, 9808-9818	153
599	Current evidence on the effect of dietary polyphenols intake on chronic diseases. 2017 , 110, 286-299	139
598	Comparison of the in vivo induction and transmission of ßsynuclein pathology by mutant ßsynuclein fibril seeds in transgenic mice. 2017 , 26, 4906-4915	20
597	The Gut and Nonmotor Symptoms in Parkinson's Disease. 2017 , 134, 787-809	29
596	Amyloid single-cell cytotoxicity assays by nanomotion detection. 2017 , 3, 17053	13
595	Recombinant ß and ßsynucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays. 2017 ,	5
594	In utero delivery of rAAV2/9 induces neuronal expression of the transgene in the brain: towards new models of Parkinson's disease. 2017 , 24, 801-809	6
593	The Genetics of Parkinson's Disease. 2017 , 98, 43-62	9
592	Liquid-liquid phase separation of the microtubule-binding repeats of the Alzheimer-related protein Tau. 2017 , 8, 275	344
591	The molecular chaperones DNAJB6 and Hsp70 cooperate to suppress ßsynuclein aggregation. 2017 , 7, 9039	40
590	Diffusion tensor imaging in Parkinson's disease: Review and meta-analysis. 2017 , 16, 98-110	127
589	ßsynucleinopathy in the Human Amygdala in Parkinson Disease: Differential Vulnerability of Somatostatin- and Parvalbumin-Expressing Neurons. 2017 , 76, 754-758	8

588	Protein Aggregation and Neurodegeneration: Tauopathies and Synucleinopathies. 2017 , 12-24	
587	Screening for TMEM230 mutations in young-onset Parkinson's disease. 2017 , 58, 239.e9-239.e10	7
586	Molecular Dynamics Study to Investigate the Dimeric Structure of the Full-Length β Synuclein in Aqueous Solution. 2017 , 57, 2281-2293	8
585	The Lewy body dementias. 278-300	
584	Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease. 2017 , 298, 202-209	54
583	β Synuclein control of mitochondrial homeostasis in human-derived neurons is disrupted by mutations associated with Parkinson's disease. 2017 , 7, 5042	60
582	Homozygous alpha-synuclein p.A53V in familial Parkinson's disease. 2017 , 57, 248.e7-248.e12	51
581	Imaging neuroinflammation to monitor β Synucleinopathy. 2017 , 16, 763-764	3
580	Cognition in Parkinson's Disease. 2017 , 133, 557-583	38
579	Intrastriatal injection of β Synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity. 2017 , 12, 40	35
578	Mutant β Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease. 2017 , 37, 47-57	20
577	An order in Lewy body disorders: Retrograde degeneration in hyperbranching axons as a fundamental structural template accounting for focal/multifocal Lewy body disease. 2017 , 37, 129-149	24
576	Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of β Synuclein Fibrils. 2017 , 91,	57
575	TMEM230 mutation analysis in Parkinson's disease in a Chinese population. 2017 , 49, 219.e1-219.e3	21
574	Lower urinary tract symptoms in Parkinson's disease: Prevalence, aetiology and management. 2017 , 35, 8-16	63
573	Calcium and Parkinson's disease. 2017 , 483, 1013-1019	118
572	Like prions: the propagation of aggregated tau and β Synuclein in neurodegeneration. 2017 , 140, 266-278	182
571	Life and death in the trash heap: The ubiquitin proteasome pathway and UCHL1 in brain aging, neurodegenerative disease and cerebral Ischemia. 2017 , 34, 30-38	46

570	Unconventional neurotrophic factors CDNF and MANF: Structure, physiological functions and therapeutic potential. 2017 , 97, 90-102	100
569	Proteolysis of β -Synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology. 2017 , 140, 662-678	41
568	Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. 2017 , 49, 60-68	500
567	c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential. 2017 , 7, 589-601	41
566	Synaptic phosphorylated β -Synuclein in dementia with Lewy bodies. 2017 , 140, 3204-3214	64
565	The Synucleinopathies: Twenty Years On. 2017 , 7, S51-S69	200
564	Speech Impairment, Phonation, Writing, Salivation, and Swallowing in Patients with Parkinson's Disease. 2017 ,	
563	Exercise-Induced Neuroprotection of the Nigrostriatal Dopamine System in Parkinson's Disease. 2017 , 9, 358	39
562	Differential Effects of Parkinson's Disease on Interneuron Subtypes within the Human Anterior Olfactory Nucleus. 2017 , 11, 113	12
561	Rab GTPases: The Key Players in the Molecular Pathway of Parkinson's Disease. 2017 , 11, 81	37
560	Iron Deposition Leads to Neuronal β -Synuclein Pathology by Inducing Autophagy Dysfunction. 2017 , 8, 1	116
559	Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders. 2016 , 10, 693	1
558	Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology. 2017 , 11, 53	2
557	Ethanolamine and Phosphatidylethanolamine: Partners in Health and Disease. 2017 , 2017, 4829180	101
556	Therapeutic implication of autophagy in neurodegenerative diseases. 2017 , 50, 345-354	56
555	Lewy and his inclusion bodies: Discovery and rejection. 2017 , 11, 198-201	5
554	Synuclein misfolding as a therapeutic target. 2017 , 21-47	
553	β -Synuclein in gut endocrine cells and its implications for Parkinson's disease. 2017 , 2,	94

552	Optimizing Parkinson's disease diagnosis: the role of a dual nuclear imaging algorithm. 2018 , 4, 5	10
551	200 Years of Parkinson's disease: what have we learnt from James Parkinson?. 2018 , 47, 209-214	23
550	Role of cellular prion protein in interneuronal amyloid transmission. 2018 , 165-167, 87-102	13
549	P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity. 2018 , 475, 1271-1293	36
548	Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson's Disease. 2018 , 12, 10-19	3
547	Shedding light on aberrant interactions - a review of modern tools for studying protein aggregates. 2018 , 285, 3604-3630	9
546	Long-lasting pathological consequences of overexpression-induced β synuclein spreading in the rat brain. 2018 , 17, e12727	21
545	Alpha-synuclein inhibits Snx3-retromer-mediated retrograde recycling of iron transporters in <i>S. cerevisiae</i> and <i>C. elegans</i> models of Parkinson's disease. 2018 , 27, 1514-1532	20
544	Alteration of putaminal fractional anisotropy in Parkinson's disease: a longitudinal diffusion kurtosis imaging study. 2018 , 60, 247-254	18
543	Association of grey matter changes with stability and flexibility of prediction in akinetic-rigid Parkinson's disease. 2018 , 223, 2097-2111	2
542	Laser Capture Microdissection. 2018 ,	5
541	Cell-Specific RNA Quantification in Human SN DA Neurons from Heterogeneous Post-mortem Midbrain Samples by UV-Laser Microdissection and RT-qPCR. 2018 , 1723, 335-360	6
540	Reversible Conformational Conversion of β Synuclein into Toxic Assemblies by Glucosylceramide. 2018 , 97, 92-107.e10	114
539	Is multiple system atrophy an infectious disease?. 2018 , 83, 10-12	13
538	Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons. 2018 , 111, 36-47	17
537	β -Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences. 2018 , 373, 195-212	61
536	Phosphorylated β Synuclein Accumulations and Lewy Body-like Pathology Distributed in Parkinson's Disease-Related Brain Areas of Aged Rhesus Monkeys Treated with MPTP. 2018 , 379, 302-315	13
535	The Convergence of Dopamine and β Synuclein: Implications for Parkinson's Disease. 2018 , 12, 1179069518761360	360

534	βSynuclein Aggregates with βAmyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects. 2018 , 55, 2653-2675	23
533	The role of regulatory T cells in nervous system pathologies. 2018 , 96, 951-968	39
532	Critical appraisal of pathology transmission in the βSynuclein fibril model of Lewy body disorders. 2018 , 299, 172-196	23
531	Parkinson's disease - the story of an eponym. <i>Nature Reviews Neurology</i> , 2018 , 14, 57-62	15 20
530	Order and disorder in the physiological membrane binding of βSynuclein. 2018 , 48, 49-57	37
529	Neurodegeneration and the ordered assembly of βSynuclein. 2018 , 373, 137-148	50
528	The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the future. 2018 , 46 Suppl 1, S1-S5	28
527	Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T βSynuclein mouse model of Parkinson's disease. 2018 , 9, 6414-6426	48
526	A Meta-Analysis of βSynuclein Multiplication in Familial Parkinsonism. 2018 , 9, 1021	46
525	Ingestion of subthreshold doses of environmental toxins induces ascending Parkinsonism in the rat. 2018 , 4, 30	27
524	Recent Advances in Biomarkers for Parkinson's Disease. 2018 , 10, 305	68
523	Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. 2018 , 21, 1341-1349	178
522	The Role of Exercise in the Management of Parkinson's Disease. 2018 , 40, 120-125	1
521	Physiological C-terminal truncation of βSynuclein potentiates the prion-like formation of pathological inclusions. 2018 , 293, 18914-18932	40
520	An integrative tissue-network approach to identify and test human disease genes. 2018 ,	31
519	Unveiling a Selective Mechanism for the Inhibition of βSynuclein Aggregation by βSynuclein. 2018 , 19,	11
518	Ineffectiveness of saxagliptin as a neuroprotective drug in 6-OHDA-lesioned rats. 2018 , 70, 1059-1068	5
517	Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes. 2018 , 33, 1432-1439	29

516	Biochemical Profiling of the Brain and Blood Metabolome in a Mouse Model of Prodromal Parkinson's Disease Reveals Distinct Metabolic Profiles. 2018 , 17, 2460-2469	32
515	Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation. 2018 ,	3
514	The brain metabolic signature of visual hallucinations in dementia with Lewy bodies. 2018 , 108, 13-24	15
513	Minimal neuropathologic diagnosis for brain banking in the normal middle-aged and aged brain and in neurodegenerative disorders. 2018 , 150, 131-141	5
512	Amyloid fibril structure of β synuclein determined by cryo-electron microscopy. 2018 , 28, 897-903	207
511	C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease. 2018 , 17, 14-21	21
510	Salidroside Promotes the Pathological β synuclein Clearance Through Ubiquitin-Proteasome System in SH-SY5Y Cells. 2018 , 9, 377	17
509	Synapsin III deficiency hampers β synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease. 2018 , 136, 621-639	33
508	Ubiquitination of alpha-synuclein filaments by Nedd4 ligases. 2018 , 13, e0200763	16
507	Can Interactions Between β synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?. 2018 , 12, 161	44
506	Localized Induction of Wild-Type and Mutant Alpha-Synuclein Aggregation Reveals Propagation along Neuroanatomical Tracts. 2018 , 92,	21
505	Ablation of tau causes an olfactory deficit in a murine model of Parkinson's disease. 2018 , 6, 57	7
504	Co-aggregation of pro-inflammatory S100A9 with β synuclein in Parkinson's disease: ex vivo and in vitro studies. 2018 , 15, 172	29
503	Determinants of dopaminergic neuron loss in Parkinson's disease. 2018 , 285, 3657-3668	127
502	LRRK2 kinase regulates β synuclein propagation via RAB35 phosphorylation. 2018 , 9, 3465	87
501	Intranasal carnosine attenuates transcriptomic alterations and improves mitochondrial function in the Thy1-aSyn mouse model of Parkinson's disease. 2018 , 125, 305-313	12
500	Altered dopamine release and monoamine transporters in Vps35 p.D620N knock-in mice. 2018 , 4, 27	38
499	CRISPR/Cas9-Mediated Generation of Guangxi Bama Minipigs Harboring Three Mutations in β synuclein Causing Parkinson's Disease. 2018 , 8, 12420	25

498	Organophosphate pesticide chlorpyrifos impairs STAT1 signaling to induce dopaminergic neurotoxicity: Implications for mitochondria mediated oxidative stress signaling events. 2018 , 117, 82-113	47
497	Peripheral and central autonomic nervous system: does the sympathetic or parasympathetic nervous system bear the brunt of the pathology during the course of sporadic PD?. 2018 , 373, 267-286	22
496	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. 2018 , 17, 597-608	68
495	The genetics of dementia with Lewy bodies. 2018 , 148, 431-440	1
494	Alteration of Diffusion-Tensor Magnetic Resonance Imaging Measures in Brain Regions Involved in Early Stages of Parkinson's Disease. 2018 , 8, 343-349	17
493	Pink1 Regulates Tyrosine Hydroxylase Expression and Dopamine Synthesis. 2018 , 63, 1361-1371	5
492	Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti- α -Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. 2018 , 75, 1206-1214	144
491	Copper Increases Brain Oxidative Stress and Enhances the Ability of 6-Hydroxydopamine to Cause Dopaminergic Degeneration in a Rat Model of Parkinson's Disease. 2019 , 56, 2845-2854	14
490	Differential insular cortex subregional vulnerability to α -Synuclein pathology in Parkinson's disease and dementia with Lewy bodies. 2019 , 45, 262-277	19
489	Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade. 2019 , 119, 1221-1322	227
488	Altered Gut Microbiome in Parkinson's Disease and the Influence of Lipopolysaccharide in a Human α -Synuclein Over-Expressing Mouse Model. 2019 , 13, 839	64
487	Neuroinflammation as a Common Feature of Neurodegenerative Disorders. 2019 , 10, 1008	221
486	Blood-brain barrier opening with focused ultrasound in experimental models of Parkinson's disease. 2019 , 34, 1252-1261	15
485	5-S-cysteinyl-dopamine, a neurotoxic endogenous metabolite of dopamine: Implications for Parkinson's disease. 2019 , 129, 104514	17
484	Exosomes from patients with Parkinson's disease are pathological in mice. 2019 , 97, 1329-1344	27
483	Icariin-mediated activation of autophagy confers protective effect on rotenone induced neurotoxicity in vivo and in vitro. 2019 , 6, 637-644	18
482	Connectomics of neurodegeneration. 2019 , 22, 1200-1202	2
481	Rifampicin and Its Derivative Rifampicin Quinone Reduce Microglial Inflammatory Responses and Neurodegeneration Induced In Vitro by α -Synuclein Fibrillary Aggregates. 2019 , 8,	21

480	Meta-Analysis of the Effects of the Catechol-O-Methyltransferase Val158/108Met Polymorphism on Parkinson's Disease Susceptibility and Cognitive Dysfunction. 2019 , 10, 644	5
479	Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease. 2019 , 25, 1045-1053	88
478	The physiological role of β Synuclein and its relationship to Parkinson's Disease. 2019 , 150, 475-486	106
477	Mutation analysis of LRP10 in Japanese patients with familial Parkinson's disease, progressive supranuclear palsy, and frontotemporal dementia. 2019 , 84, 235.e11-235.e16	5
476	Chronic nigral neuromodulation aggravates behavioral deficits and synaptic changes in an β Synuclein based rat model for Parkinson's disease. 2019 , 7, 160	5
475	Behavioral symptomatology and psychopharmacology of Lewy body dementia. 2019 , 165, 59-70	4
474	Animal Models for Parkinson's Disease Research: Trends in the 2000s. 2019 , 20,	47
473	Different Heat Shock Proteins Bind β Synuclein With Distinct Mechanisms and Synergistically Prevent Its Amyloid Aggregation. 2019 , 13, 1124	14
472	β Synuclein RT-QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies. 2019 , 6, 2120-2126	42
471	Complex of EGCG with Cu(II) Suppresses Amyloid Aggregation and Cu(II)-Induced Cytotoxicity of β Synuclein. 2019 , 24,	19
470	Alterations in Blood Monocyte Functions in Parkinson's Disease. 2019 , 34, 1711-1721	33
469	Probiotics for Parkinson's Disease. 2019 , 20,	56
468	Preclinical development of a high affinity β Synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular β Synuclein and attenuate β Synuclein spreading in vivo. 2019 , 132, 104582	31
467	Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of Finns aged 85. 2019 , 138, 771-782	19
466	Bioenergetics and Autophagic Imbalance in Patients-Derived Cell Models of Parkinson Disease Supports Systemic Dysfunction in Neurodegeneration. 2019 , 13, 894	16
465	Altered Gut Microbiome and Intestinal Pathology in Parkinson's Disease. 2019 , 12, 67-83	36
464	Burden of Disease and Current Management of Dementia with Lewy Bodies: A Literature Review. 2019 , 8, 289-305	9
463	Characterization of the Basic Membrane Properties of Neurons of the Rat Dorsal Motor Nucleus of the Vagus in Paraquat-Induced Models of Parkinsonism. 2019 , 418, 122-132	3

462	Toward the discovery and development of effective modulators of β -synuclein amyloid aggregation. 2019 , 167, 10-36	25
461	Dementia with Lewy bodies: an update and outlook. 2019 , 14, 5	100
460	Tocotrienol Rich Fraction Supplementation Modulate Brain Hippocampal Gene Expression in APP ^{swe} /PS1 ^{dE9} Alzheimer's Disease Mouse Model. 2019 , 70, S239-S254	10
459	Assembly of β -synuclein aggregates on phospholipid bilayers. 2019 , 1867, 802-812	20
458	Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. 2019 , 22, 1099-1109	323
457	Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease. 2019 , 142, 2380-2401	21
456	A secret that underlies Parkinson's disease: The damaging cycle. 2019 , 129, 104484	11
455	Natural Antioxidant Anthocyanins-A Hidden Therapeutic Candidate in Metabolic Disorders with Major Focus in Neurodegeneration. 2019 , 11,	50
454	Linking the Endoplasmic Reticulum to Parkinson's Disease and Alpha-Synucleinopathy. 2019 , 13, 560	49
453	Interrogating Parkinson's disease associated redox targets: Potential application of CRISPR editing. 2019 , 144, 279-292	9
452	Effects of in vivo conditions on amyloid aggregation. 2019 , 48, 3946-3996	86
451	Comparative analyses of the in vivo induction and transmission of β -synuclein pathology in transgenic mice by MSA brain lysate and recombinant β -synuclein fibrils. 2019 , 7, 80	19
450	Altered gastric tone and motility response to brain-stem dopamine in a rat model of parkinsonism. 2019 , 317, G1-G7	7
449	LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?. 2019 , 47, 827-838	12
448	In Vitro Models of Brain Disorders. 2019 , 22, 19-49	0
447	Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases. 2019 , 94, 892-905	53
446	Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson's disease. 2019 , 12, 49	27
445	Quantitative Characterization of β -Synuclein Aggregation in Living Cells through Automated Microfluidics Feedback Control. 2019 , 27, 916-927.e5	21

444	Influence of analytic techniques on comparing DTI-derived measurements in early stage Parkinson's disease. 2019 , 5, e01481	14
443	Neurophysiology of the brain stem in Parkinson's disease. 2019 , 121, 1856-1864	9
442	Microbiome, Parkinson's Disease and Molecular Mimicry. 2019 , 8,	43
441	Naturally occurring antibodies target Parkinson disease pathology. <i>Nature Reviews Neurology</i> , 2019 , 15, 186-187	15 1
440	The Parkinson's disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4. 2019 , 9, 4515	12
439	The Neuropathological and Clinical Diagnostic Criteria of Chronic Traumatic Encephalopathy: A Critical Examination in Relation to Other Neurodegenerative Diseases. 2019 , 68, 591-608	6
438	Entanglement of Genetics and Epigenetics in Parkinson's Disease. 2019 , 13, 277	28
437	Coordination of Platinum to β Synuclein Inhibits Filamentous Aggregation in Solution. 2019 , 20, 1953-1958	2
436	Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology. 2019 , 24,	17
435	Differential Aggregation and Phosphorylation of Alpha Synuclein in Membrane Compartments Associated With Parkinson Disease. 2019 , 13, 382	22
434	Calcium, Dopamine and Neuronal Calcium Sensor 1: Their Contribution to Parkinson's Disease. 2019 , 12, 55	14
433	Involvement of aberrant regulation of epigenetic mechanisms in the pathogenesis of Parkinson's disease and epigenetic-based therapies. 2019 , 234, 19307-19319	18
432	LRRK2 modifies β Syn pathology and spread in mouse models and human neurons. 2019 , 137, 961-980	78
431	Recapitulating Parkinson's disease pathology in a three-dimensional human neural cell culture model. 2019 , 12,	16
430	Mass Spectrometric Analysis of Lewy Body-Enriched β Synuclein in Parkinson's Disease. 2019 , 18, 2109-2120	19
429	Multiple molecular pathways stimulating macroautophagy protect from alpha-synuclein-induced toxicity in human neurons. 2019 , 149, 13-26	9
428	Neurotoxic effects of MPTP on mouse cerebral cortex: Modulation of neuroinflammation as a neuroprotective strategy. 2019 , 96, 1-9	10
427	Dissecting β Synuclein inclusion pathology diversity in multiple system atrophy: implications for the prion-like transmission hypothesis. 2019 , 99, 982-992	11

426	In Situ Peroxidase Labeling and Mass Spectrometry of Alpha-Synuclein in Rat Cortical Neurons. 2019 , 1948, 235-246	
425	The Effects of rs894278 on Resting-State Brain Activity in Parkinson's Disease. 2019 , 13, 47	9
424	Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson's disease with dementia. 2019 , 9, 19648	6
423	Simultaneous quantification of tau and β synuclein in cerebrospinal fluid by high-resolution mass spectrometry for differentiation of Lewy Body Dementia from Alzheimer's Disease and controls. 2019 , 144, 6342-6351	7
422	Homogenous generation of dopaminergic neurons from multiple hiPSC lines by transient expression of transcription factors. 2019 , 10, 898	22
421	Local vulnerability and global connectivity jointly shape neurodegenerative disease propagation. 2019 , 17, e3000495	37
420	The Challenge and Opportunity to Diagnose Parkinson's Disease in Midlife. 2019 , 10, 1328	7
419	Dysregulated Long Non-coding RNAs in Parkinson's Disease Contribute to the Apoptosis of Human Neuroblastoma Cells. 2019 , 13, 1320	22
418	Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. 2019 , 12, 299	91
417	Association of LAG3 genetic variation with an increased risk of PD in Chinese female population. 2019 , 16, 270	11
416	Luminescent conjugated oligothiophenes distinguish between β synuclein assemblies of Parkinson's disease and multiple system atrophy. 2019 , 7, 193	19
415	Dementia with Lewy bodies - from scientific knowledge to clinical insights. <i>Nature Reviews Neurology</i> , 2019 , 15, 103-112	15 26
414	Lack of association between dopamine transporter loss and non-motor symptoms in patients with Parkinson's disease: a detailed PET analysis of 12 striatal subregions. 2019 , 40, 311-317	19
413	Guanosine Protects Striatal Slices Against 6-OHDA-Induced Oxidative Damage, Mitochondrial Dysfunction, and ATP Depletion. 2019 , 35, 475-483	11
412	The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration. 2019 , 34, 167-179	36
411	Exploring the Roles of Post-Translational Modifications in the Pathogenesis of Parkinson's Disease Using Synthetic and Semisynthetic Modified β Synuclein. 2019 , 10, 910-921	12
410	Propagation of β Synuclein Strains within Human Reconstructed Neuronal Network. 2019 , 12, 230-244	59
409	New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics. 2019 , 59, 32-38	20

408	Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives. 2019 , 56, 4799-4811	17
407	Development of an aggregate-selective, human-derived β synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models. 2019 , 124, 276-288	74
406	Microbiome-microglia connections via the gut-brain axis. 2019 , 216, 41-59	131
405	Admixing MPTP-resistant and MPTP-vulnerable mice enhances striatal field potentials and calbindin-D28K expression to avert motor behaviour deficits. 2019 , 360, 216-227	4
404	Alzheimer's Disease and Dementia. 2019 , 25-82	0
403	Parkinson's Disease. 2019 , 83-121	2
402	Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities. 2019 , 30, 1450-1499	50
401	A clinical-anatomical signature of Parkinson's disease identified with partial least squares and magnetic resonance imaging. 2019 , 190, 69-78	32
400	La maladie de Parkinson est aussi une maladie du tube digestif. 2020 , 204, 66-71	
399	Computational prediction and redesign of aberrant protein oligomerization. 2020 , 169, 43-83	5
398	Microglia, Lifestyle Stress, and Neurodegeneration. 2020 , 52, 222-240	82
397	Regulation of β synuclein by chaperones in mammalian cells. 2020 , 577, 127-132	79
396	Neuroprotective effect of crocin against rotenone-induced Parkinson's disease in rats: Interplay between PI3K/Akt/mTOR signaling pathway and enhanced expression of miRNA-7 and miRNA-221. 2020 , 164, 107900	37
395	Identification of novel flavonoid inhibitor of Catechol-O-Methyltransferase enzyme by molecular screening, quantum mechanics/molecular mechanics and molecular dynamics simulations. 2020 , 38, 5307-5319	5
394	Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson's disease. 2020 , 139, 319-345	9
393	Sex differences in movement disorders. <i>Nature Reviews Neurology</i> , 2020 , 16, 84-96	15 56
392	Differential Diagnosis of Multiple System Atrophy-Parkinsonism and Parkinson's Disease Using β synuclein and External Anal Sphincter Electromyography. 2020 , 11, 1043	0
391	Neuroprotective Effect of Curcumin on the Nigrostriatal Pathway in a 6-Hydroxydopamine-Induced Rat Model of Parkinson's Disease is Mediated by α -Nicotinic Receptors. 2020 , 21,	12

390	Toxic Metamorphosis-How Changes from Lysosomal to Cytosolic pH Modify the Alpha-Synuclein Aggregation Pattern. 2020 , 21, 4673-4684	8
389	Classic and evolving animal models in Parkinson's disease. 2020 , 199, 173060	6
388	Genetic variants of TAS2R38 bitter taste receptor associate with distinct gut microbiota traits in Parkinson's disease: A pilot study. 2020 , 165, 665-674	12
387	Performance of Force-Field- and Machine Learning-Based Scoring Functions in Ranking MAO-B Protein-Inhibitor Complexes in Relevance to Developing Parkinson's Therapeutics. 2020 , 21,	4
386	Preclinical models of disease and multimorbidity with focus upon cardiovascular disease and dementia. 2020 , 192, 111361	2
385	Beneficial effects of cysteamine in Thy1- α Syn mice and induced pluripotent stem cells with a SNCA gene triplication. 2020 , 145, 105042	5
384	Deciphering the robustness of pyrazolo-pyridine carboxylate core structure-based compounds for inhibiting α Synuclein in transgenic <i>C. elegans</i> model of Synucleinopathy. 2020 , 28, 115640	3
383	Lysosomal Storage Disorders Shed Light on Lysosomal Dysfunction in Parkinson's Disease. 2020 , 21,	9
382	Quercetin Disaggregates Prion Fibrils and Decreases Fibril-Induced Cytotoxicity and Oxidative Stress. 2020 , 12,	2
381	Intracellular A53T Mutant α Synuclein Impairs Adult Hippocampal Newborn Neuron Integration. 2020 , 8, 561963	2
380	Mitochondrial hyperactivity as a potential therapeutic target in Parkinson's disease. 2020 , 4, 117-120	4
379	Different Perivascular Space Burdens in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease. 2020 , 12, 580853	4
378	Keeping α Synuclein at Bay: A More Active Role of Molecular Chaperones in Preventing Mitochondrial Interactions and Transition to Pathological States?. 2020 , 10,	4
377	Current Status of Stem Cell-Derived Therapies for Parkinson's Disease: From Cell Assessment and Imaging Modalities to Clinical Trials. 2020 , 14, 558532	9
376	TRIM11 Prevents and Reverses Protein Aggregation and Rescues a Mouse Model of Parkinson's Disease. 2020 , 33, 108418	10
375	Optical spectroscopy and microscopy techniques for assessment of neurological diseases. 2020 , 1-40	2
374	Mechanistic Insights into the Role of Molecular Chaperones in Protein Misfolding Diseases: From Molecular Recognition to Amyloid Disassembly. 2020 , 21,	5
373	Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies. 2020 , 72, 1195-1217	12

372	From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson's Disease: Lessons From LRRK2. 2020 , 14, 158	7
371	Parkinson disease and the gut: new insights into pathogenesis and clinical relevance. 2020 , 17, 673-685	44
370	Parkinson's disease-related phosphorylation at Tyr39 rearranges α -synuclein amyloid fibril structure revealed by cryo-EM. 2020 , 117, 20305-20315	48
369	α -Synuclein in Parkinson's Disease: Does a Prion-Like Mechanism of Propagation from Periphery to the Brain Play a Role?. 2021 , 27, 367-387	3
368	Skin Temperature in Parkinson's Disease Measured by Infrared Thermography. 2020 , 2020, 2349469	6
367	Gut Microbiota Approach-A New Strategy to Treat Parkinson's Disease. 2020 , 10, 570658	14
366	Androgen Therapy in Neurodegenerative Diseases. 2020 , 4, bvaa120	12
365	AggreCount: an unbiased image analysis tool for identifying and quantifying cellular aggregates in a spatially defined manner. 2020 , 295, 17672-17683	8
364	Alpha-Synuclein in Alcohol Use Disorder, Connections with Parkinson's Disease and Potential Therapeutic Role of 5' Untranslated Region-Directed Small Molecules. 2020 , 10,	3
363	Endoplasmic Reticulum Stress and Unfolded Protein Response in Neurodegenerative Diseases. 2020 , 21,	49
362	GDNF/RET signaling in dopamine neurons in vivo. 2020 , 382, 135-146	5
361	A Critical LRRK at the Synapse? The Neurobiological Function and Pathophysiological Dysfunction of LRRK2. 2020 , 13, 153	8
360	The role of the cellular prion protein in the uptake and toxic signaling of pathological neurodegenerative aggregates. 2020 , 175, 297-323	1
359	Alpha-synuclein Levels in the Differential Diagnosis of Lewy Bodies Dementia and Other Neurodegenerative Disorders: A Meta-analysis. 2020 , 34, 220-224	7
358	Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy. 2020 , 8, 150	16
357	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Induced Parkinson's Disease in Mouse: Potential Association between Neurotransmitter Disturbance and Gut Microbiota Dysbiosis. 2020 , 11, 3366-3376	7
356	The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinson's Disease. 2020 , 8, 580634	12
355	RING-finger protein 166 plays a novel pro-apoptotic role in neurotoxin-induced neurodegeneration via ubiquitination of XIAP. 2020 , 11, 939	5

354	PINK1/PARKIN signalling in neurodegeneration and neuroinflammation. 2020 , 8, 189	60
353	Impaired Phasic Discharge of Locus Coeruleus Neurons Based on Persistent High Tonic Discharge-A New Hypothesis With Potential Implications for Neurodegenerative Diseases. 2020 , 11, 371	9
352	Alteration in the Expression of Parkinson-Related Genes in Rat Hippocampus by Exercise and Morphine Treatments. 2020 , 56, 502-508	
351	Accumulation of HAX-1 and PARL in brainstem- and cortical-type Lewy bodies in Parkinson's disease and dementia with Lewy bodies. 2020 , 415, 116928	2
350	Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. 2020 , 29, 864-872	5
349	Radiosynthesis and evaluation of 4-(6-[F]Fluoro-4-(5-isopropoxy-1-indazol-3-yl)pyridin-2-yl)morpholine as a novel radiotracer candidate targeting leucine-rich repeat kinase 2. 2020 , 11, 676-684	2
348	The Evolution-Driven Signature of Parkinson's Disease. 2020 , 43, 475-492	8
347	The human olfactory system in two proteinopathies: Alzheimer's and Parkinson's diseases. 2020 , 9, 22	22
346	Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous mutations and ameliorated by genetic knock-out. 2020 , 2, fcz052	8
345	Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts. 2020 , 20, 73	12
344	Potential Roles of Exosomes in Parkinson's Disease: From Pathogenesis, Diagnosis, and Treatment to Prognosis. 2020 , 8, 86	47
343	Movement Disorders Phenomenology. 2020 ,	
342	Cryo-EM structure of full-length α synuclein amyloid fibril with Parkinson's disease familial A53T mutation. 2020 , 30, 360-362	39
341	α Synuclein filaments from transgenic mouse and human synucleinopathy-containing brains are major seed-competent species. 2020 , 295, 6652-6664	10
340	The Quest for Cellular Prion Protein Functions in the Aged and Neurodegenerating Brain. 2020 , 9,	8
339	Interaction of Oxidative Stress and Misfolded Proteins in the Mechanism of Neurodegeneration. 2020 , 10,	23
338	A Self-Assembled α Synuclein Nanoscavenger for Parkinson's Disease. 2020 , 14, 1533-1549	33
337	Chemical Chaperones as Novel Drugs for Parkinson's Disease. 2020 , 26, 408-421	15

336	Miro: A molecular switch at the center of mitochondrial regulation. 2020 , 29, 1269-1284	18
335	pH-Dependent Aggregation in Intrinsically Disordered Proteins Is Determined by Charge and Lipophilicity. 2020 , 9,	18
334	Immunotherapy for Parkinson's disease. 2020 , 137, 104760	27
333	The N-terminal Acetylation of α -Synuclein Changes the Affinity for Lipid Membranes but not the Structural Properties of the Bound State. 2020 , 10, 204	22
332	Selective neuronal vulnerability in Parkinson's disease. 2020 , 252, 61-89	12
331	Diffusion Kurtosis Imaging of Microstructural Changes in Gray Matter Nucleus in Parkinson Disease. 2020 , 11, 252	5
330	Mass Spectrometry-Based Protein Footprinting for Higher-Order Structure Analysis: Fundamentals and Applications. 2020 , 120, 4355-4454	56
329	Structural basis of the interplay between α -Synuclein and Tau in regulating pathological amyloid aggregation. 2020 , 295, 7470-7480	17
328	α -Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment. 2020 , 15, 27	16
327	Noncanonical Roles of h-syn (A53T) in the Pathogenesis of Parkinson's Disease: Synaptic Pathology and Neuronal Aging. 2020 , 2020, 6283754	2
326	A role for α -Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson's disease. 2020 , 15, 24	10
325	The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease. 2020 , 9,	23
324	From inflammasome to Parkinson's disease: Does the NLRP3 inflammasome facilitate exosome secretion and exosomal alpha-synuclein transmission in Parkinson's disease?. 2021 , 336, 113525	8
323	Detergent-insoluble inclusion constitutes the first pathology in PFN1 transgenic rats. 2021 , 157, 1244-1252	3
322	Remodeling without destruction: non-proteolytic ubiquitin chains in neural function and brain disorders. 2021 , 26, 247-264	6
321	Pathophysiology of Parkinson's disease: Mitochondria, alpha-synuclein and much more□ 2021 , 177, 260-271	6
320	Role of astroglial toll-like receptors (TLRs) in central nervous system infections, injury and neurodegenerative diseases. 2021 , 91, 740-755	43
319	Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease. 2021 , 30, 201-209	1

318	Detecting and targeting neurodegenerative disorders using electrospun nanofibrous matrices: current status and applications. 2021 , 29, 476-490	1
317	Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions. 2021 , 11, 71-92	7
316	Disruption of neocortical synchronisation during slow-wave sleep in the rotenone model of Parkinson's disease. 2021 , 30, e13170	2
315	Phospholipids Uniquely Modify Secondary Structure of β Synuclein Oligomers.	
314	CRISPR-Cas9 for treating hereditary diseases. 2021 , 181, 165-183	4
313	and Polymorphisms as Risk Factors for Parkinson's Disease. 2021 , 10,	11
312	Priming mesenchymal stem cells with uric acid enhances neuroprotective properties in parkinsonian models. 2021 , 12, 20417314211004816	2
311	Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders. 2021 , 291-310	
310	Reverse engineering Lewy bodies: how far have we come and how far can we go?. 2021 , 22, 111-131	47
309	An Update on Medical and Surgical Treatments of Parkinson's Disease. 2021 , 12, 1021-1035	2
308	The Membrane Interactions of Synuclein: Physiology and Pathology. 2021 , 16, 465-485	12
307	Akkermansia muciniphila secretome promotes β Synuclein aggregation in enteroendocrine cells.	1
306	Cell senescence in neuropathology: A focus on neurodegeneration and tumours. 2021 , 47, 359-378	9
305	Heterogeneity in β Synuclein fibril activity correlates to disease phenotypes in Lewy body dementia. 2021 , 141, 547-564	9
304	Microsleep disturbances are associated with noradrenergic dysfunction in Parkinson's disease. 2021 , 44,	6
303	The Cytotoxic Effect of β Synuclein Aggregates. 2021 , 22, 526-532	1
302	β Synuclein plasma membrane localization correlates with cellular phosphatidylinositol polyphosphate levels. 2021 , 10,	4
301	microRNA signatures in prodromal REM sleep behavior disorder and early Parkinson's disease as noninvasive biomarkers. 2021 , 78, 160-168	1

300	How Is the Fidelity of Proteins Ensured in Terms of Both Quality and Quantity at the Endoplasmic Reticulum? Mechanistic Insights into E3 Ubiquitin Ligases. 2021 , 22,	0
299	Influence of Lipid Membranes on β Synuclein Aggregation. 2021 , 12, 825-830	9
298	High-throughput behavioral screen in <i>C. elegans</i> reveals Parkinson's disease drug candidates. 2021 , 4, 203	8
297	Is Attention-Deficit/Hyperactivity Disorder a Risk Syndrome for Parkinson's Disease?. 2021 , 29, 142-158	3
296	Modelling Parkinson's Disease: iPSCs towards Better Understanding of Human Pathology. 2021 , 11,	7
295	β Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease. 2021 , 6,	15
294	Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of β Synucleinopathy. 2021 , 18, 962-978	7
293	Knocking out alpha-synuclein in melanoma cells dysregulates cellular iron metabolism and suppresses tumor growth. 2021 , 11, 5267	6
292	ATP13A2 Regulates Cellular β Synuclein Multimerization, Membrane Association, and Externalization. 2021 , 22,	3
291	Super-resolving Microscopy in Neuroscience. 2021 , 121, 11971-12015	12
290	Novel insights in the pathophysiology of β Synuclein dysregulation on D2 receptor activity contributing to the vulnerability of dopamine neurons.	
289	Preclinical Detection of Alpha-Synuclein Seeding Activity in the Colon of a Transgenic Mouse Model of Synucleinopathy by RT-QuIC. 2021 , 13,	2
288	Genes Implicated in Familial Parkinson's Disease Provide a Dual Picture of Nigral Dopaminergic Neurodegeneration with Mitochondria Taking Center Stage. 2021 , 22,	6
287	A Propagated Skeleton Approach to High Throughput Screening of Neurite Outgrowth for In Vitro Parkinson's Disease Modelling. 2021 , 10,	1
286	LRP10 interacts with SORL1 in the intracellular vesicle trafficking pathway in non-neuronal brain cells and localises to Lewy bodies in Parkinson's disease and dementia with Lewy bodies. 2021 , 142, 117-137	0
285	MicroRNA Dysregulation in Parkinson's Disease: A Narrative Review. 2021 , 15, 660379	7
284	Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein. 2021 , 9, 64	2
283	In situ architecture of neuronal β Synuclein inclusions. 2021 , 12, 2110	24


282	Parkinson Hastalıklarında İncelenen PreNAC Fibril Kesiti ve Onun A53C, A53E, A53G, A53T, A53V Mutasyonlarının Yapısal Kararlılık Araştırması 66-76	
281	Karyopherin abnormalities in neurodegenerative proteinopathies. 2021 , 144, 2915-2932	2
280	Cingulate networks associated with gray matter loss in Parkinson's disease show high expression of cholinergic genes in the healthy brain. 2021 , 53, 3727-3739	2
279	Kinetic Monitoring Of Neuronal Stress Response To Proteostasis Dysfunction.	1
278	Unravelling the Structural Organization of Individual α -Synuclein Oligomers Grown in the Presence of Phospholipids. 2021 , 12, 4407-4414	11
277	Glucose Metabolic Dysfunction in Neurodegenerative Diseases-New Mechanistic Insights and the Potential of Hypoxia as a Prospective Therapy Targeting Metabolic Reprogramming. 2021 , 22,	14
276	Effect of gender in the onset and progression of Parkinson's disease. 2021 ,	
275	The gut-brain connection in the pathogenicity of Parkinson disease: Putative role of autophagy. 2021 , 753, 135865	5
274	FGF, Mechanism of Action, Role in Parkinson's Disease, and Therapeutics. 2021 , 12, 675725	2
273	Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity. 2021 , 26,	5
272	Local Translation in Nervous System Pathologies. 2021 , 15, 689208	2
271	Biomarkers for neurodegenerative diseases. 2021 , 27, 954-963	69
270	α -Synuclein Strains: Does Amyloid Conformation Explain the Heterogeneity of Synucleinopathies?. 2021 , 11,	5
269	The Olfactory System as Marker of Neurodegeneration in Aging, Neurological and Neuropsychiatric Disorders. 2021 , 18,	2
268	Gastroparesis in Parkinson Disease: Pathophysiology, and Clinical Management. 2021 , 11,	1
267	Domain-Independent Inhibition of CBP/p300 Attenuates α -Synuclein Aggregation. 2021 , 12, 2273-2279	1
266	Co-editing PINK1 and DJ-1 Genes Via Adeno-Associated Virus-Delivered CRISPR/Cas9 System in Adult Monkey Brain Elicits Classical Parkinsonian Phenotype. 2021 , 37, 1271-1288	6
265	Humanized Mice for Infectious and Neurodegenerative disorders. 2021 , 18, 13	3

264	Alpha-Synuclein Post-translational Modifications: Implications for Pathogenesis of Lewy Body Disorders. 2021 , 13, 690293	3
263	Roles for β Synuclein in Gene Expression. 2021 , 12,	2
262	Neurodegenerative disorders and gut-brain interactions. 2021 , 131,	10
261	Molecular Communication Between Neuronal Networks and Intestinal Epithelial Cells in Gut Inflammation and Parkinson's Disease. 2021 , 8, 655123	2
260	Neuropeptide-S prevents 6-OHDA-induced gastric dysmotility in rats. 2021 , 1762, 147442	1
259	Fibrillar β Synuclein induces neurotoxic astrocyte activation via RIP kinase signaling and NF- κ B. 2021 , 12, 756	4
258	Dopamine-dependent early synaptic and motor dysfunctions induced by β Synuclein in the nigrostriatal circuit. 2021 ,	7
257	Beyond Just Connectivity - Neuronal Activity Drives β Synuclein Pathology. 2021 , 36, 1487-1488	1
256	Synaptic decline precedes dopaminergic neuronal loss in human midbrain organoids harboring a triplication of the SNCA gene.	3
255	DNAJB6b is Downregulated in Synucleinopathies. 2021 , 11, 1791-1803	
254	Elevated plasma miR-133b and miR-221-3p as biomarkers for early Parkinson's disease. 2021 , 11, 15268	3
253	Unravelling the role of gut microbiota in Parkinson's disease progression: Pathogenic and therapeutic implications. 2021 , 168, 100-112	6
252	Bilobalide: A review of its pharmacology, pharmacokinetics, toxicity, and safety. 2021 , 35, 6114-6130	4
251	The Human Hippocampus in Parkinson's Disease: An Integrative Stereological and Proteomic Study. 2021 , 11, 1345-1365	3
250	β Synuclein-induced dysregulation of neuronal activity contributes to murine dopamine neuron vulnerability. 2021 , 7, 76	1
249	Disease-, region- and cell type specific diversity of β Synuclein carboxy terminal truncations in synucleinopathies. 2021 , 9, 146	1
248	Effects of Weak Nonspecific Interactions with ATP on Proteins. 2021 , 143, 11982-11993	6
247	Hearing Loss in Neurological Disorders. 2021 , 9, 716300	3

246	Parkinson's Disease-Associated, Sex-specific Changes in DNA Methylation at PARK7 (DJ-1), ATXN1, SLC17A6, NR4A2, and PTPRN2 in Cortical Neurons.	
245	The role of neuroimaging in Parkinson's disease. 2021 , 159, 660-689	4
244	Synergistic Effect of Serotonin 1A and Serotonin 1B/D Receptor Agonists in the Treatment of L-DOPA-Induced Dyskinesia in 6-Hydroxydopamine-Lesioned Rats.	
243	Impaired brain insulin signalling in Parkinson's disease. 2021 ,	1
242	The transcription factor BCL11A defines distinct subsets of midbrain dopaminergic neurons. 2021 , 36, 109697	2
241	β-Synuclein inhibits Snx3-retromer retrograde trafficking of the conserved membrane-bound proprotein convertase Kex2 in the secretory pathway of <i>Saccharomyces cerevisiae</i> . 2021 ,	1
240	Parkinson's disease and the gut: Models of an emerging relationship. 2021 , 132, 325-344	1
239	Seeking progress in disease modification in Parkinson disease. 2021 , 90, 134-141	4
238	Spontaneous nucleation and fast aggregate-dependent proliferation of β-synuclein aggregates within liquid condensates at physiological pH.	5
237	DNAJB6 suppresses alpha-synuclein induced pathology in an animal model of Parkinson's disease. 2021 , 158, 105477	3
236	Potential applications of nanomedicine for treating Parkinson's disease. 2021 , 66, 102793	3
235	A growth-factor-activated lysosomal K channel regulates Parkinson's pathology. 2021 , 591, 431-437	15
234	The Association between Early-Life Gut Microbiota and Long-Term Health and Diseases. 2021 , 10,	41
233	Parkinson's disease: Genetic-driven therapeutic approaches. 2021 , 135-159	
232	Parkinsonism. 2021 , 82-120.e21	
231	Recording In-Cell NMR-Spectra in Living Mammalian Cells. 2020 , 2141, 857-871	4
230	Parkinson's Disease and Aging. 2016 , 229-255	1
229	Autophagy and Prion Disease. 2020 , 1207, 75-85	1

228	Complexins. 2017 ,	1
227	Specific Knockdown of β Synuclein by Peptide-Directed Proteasome Degradation Rescued Its Associated Neurotoxicity. 2020 , 27, 751-762.e4	15
226	Membrane Architecture in the Spotlight of Correlative Microscopy. 2020 , 30, 577-587	6
225	CHAPTER 8:Synuclein and Parkinson's Disease: An Update. 2013 , 175-216	6
224	The emerging role of β Synuclein truncation in aggregation and disease. 2020 , 295, 10224-10244	43
223	RT-QuIC-based detection of alpha-synuclein seeding activity in brains of dementia with Lewy Body patients and of a transgenic mouse model of synucleinopathy. 2020 , 14, 88-94	10
222	On the role of the cellular prion protein in the uptake and signaling of pathological aggregates in neurodegenerative diseases. 2020 , 14, 257-270	4
221	Lewy pathology in Parkinson's disease consists of a crowded organellar, membranous medley.	17
220	A clinical-anatomical signature of Parkinson's Disease identified with partial least squares and magnetic resonance imaging.	1
219	Functional and molecular early enteric biomarkers for Parkinson's disease in mice and men.	2
218	RIT2 reduces LRRK2 kinase activity and protects against alpha-synuclein neuropathology.	1
217	Phospholipid membranes promote the early stage assembly of β Synuclein aggregates.	2
216	Local vulnerability and global connectivity jointly shape neurodegenerative disease propagation.	1
215	Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease.	7
214	Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular β Synuclein transfer. 2019 , 129, 3738-3753	68
213	Activation of tyrosine kinase c-Abl contributes to β Synuclein-induced neurodegeneration. 2016 , 126, 2970-88	88
212	Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson's Disease. 2016 , 11, e0157755	29
211	Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. 2017 , 12, e0181844	15

210	A novel panel of β synuclein antibodies reveal distinctive staining profiles in synucleinopathies. 2017 , 12, e0184731	32
209	Olfaction and Colour Vision: What Can They Tell Us about Parkinson's Disease?. 2018 , 119, 85-96	5
208	Immunotherapy Targeting Neurodegenerative Proteinopathies: β Synucleinopathies and Tauopathies. 2020 , 13, 11-19	14
207	-GFP Knock-In Mice Reflect Patterns of Endogenous Expression and Pathological Seeding. 2020 , 7,	8
206	Parkinson's Disease: Etiology, Neuropathology, and Pathogenesis. 3-26	45
205	Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus. 2014 , 13, 1280-93	81
204	Neuroprotection of Rotenone-Induced Parkinsonism by Ursolic Acid in PD Mouse Model. 2020 , 19, 527-540	34
203	Cellular models, genomic technologies and clinical practice: a synthesis of knowledge for the study of the mechanisms, diagnostics and treatment of Parkinson's disease. 2017 , XII,	3
202	Subcellular localization of alpha-synuclein aggregates and their interaction with membranes. 2018 , 13, 1136-1144	32
201	Emerging roles of 14-3-3 in the brain disorder. 2020 , 53, 500-511	3
200	Inhibition of synucleinopathic seeding by rationally designed inhibitors. 2020 , 9,	29
199	Non-monotonic fibril surface occlusion by GFP tags from coarse-grained molecular simulations.	
198	Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxypropyl- β Cyclodextrin Treatment. 2021 ,	7
197	Biomaterial Strategies for Restorative Therapies in Parkinson's Disease. 2021 , 12, 4224-4235	2
196	Quantitative study of alpha-synuclein prion-like spreading in fully oriented reconstructed neural networks reveals non-synaptic dissemination of seeding aggregates.	0
195	Membrane lipid raft homeostasis is directly linked to neurodegeneration. 2021 ,	2
194	What substance P might tell us about the prognosis and mechanism of Parkinson's disease?. 2021 , 131, 899-911	0
193	Neuroprotection Versus Neurotoxicity. 2014 , 145-172	0

- 192 Movement Disorders: Focus on Parkinson's Disease and Related Disorders. **2016**, 103-125
- 191 Der Begriff der Nerventätigkeit in der Pathogenese neurodegenerativer Erkrankungen und ganzheitliche Therapiemöglichkeiten bei M. Parkinson. **2016**, 69, 345-354 6
- 190 Krankheiten der Basalganglien. **2016**, 589-623 0
- 189  "Barcode". **2017**, 4-14
- 188 Insular cortex sub-region-dependent distribution pattern of β synuclein immunoreactivity in Parkinson's disease and dementia with Lewy bodies. 1
- 187 Structural propensity database of proteins.
- 186 Alpha-Synuclein. 1-12
- 185 Reconstitution of Helical Soluble β Synuclein through Transient Interaction with Lipid Interfaces.
- 184 Changes in the Immune System in Parkinson's Disease. **2018**, 1-21
- 183 Prion-Like Propagation in Neurodegenerative Diseases. **2018**, 189-242
- 182 Atxn2-CAG100-knock-in affects mouse lifespan and vestibulo-cerebellar function via neural disconnection.
- 181 Immunohistochemical Revealing of Alpha-Synuclein in Synaptic Contact Area of Hippocampal CA3 Zone. **2018**, 7, 23-28
- 180 Changes in the Immune System in Parkinson's Disease. **2019**, 2353-2373
- 179 LRRK2 modifies β syn pathology and spread in mouse models and human neurons.
- 178 Parkinson's disease-related phosphorylation at Tyr39 rearranges β synuclein amyloid fibril structure revealed by cryo-EM.
- 177 Snca-GFP knock-in mice reflect patterns of endogenous expression and pathological seeding.
- 176 Orally Administered Nanotherapeutics For Parkinson's Disease: An Old Delivery System Yet More Acceptable. **2020**, 26, 2280-2290 0
- 175 In situ architecture of neuronal β Synuclein inclusions.

- 174 Saturated Proteostasis and Nuclear Injuries Defeat Homeostatic Potentials of α -Synuclein Filaments.
- 173 The role of the gastrointestinal system and gut microbiota in Parkinson's disease. **2020**, 569-582
- 172 Phenomenology of Atypical Parkinsonism. **2020**, 37-61
- 171 CHAPTER 11:Chemical Probes in Cellular Assays for Target Validation and Screening in Neurodegeneration. **2020**, 276-319
- 170 Methods for early diagnosis of Parkinson's disease. **2020**, 20, 62-67
- 169 Knockdown transgenic Drosophila and Parkinson's disease. **2020**, 643-661
- 168 JN403, an alpha-7-nicotine-acetylcholine-receptor agonist, reduces alpha-synuclein induced inflammatory parameters of microglia but fails to attenuate the reduction of TH positive nigral neurons in a focal alpha-synuclein overexpression mouse model of Parkinson's disease.
- 167 α -Synuclein plasma membrane localization correlates with cellular phosphatidylinositol polyphosphate levels. 1
- 166 Alpha-synuclein'in PreNAC(46-56) Fibril Bili Moleküler Dinamik Simülasyon Yöntemi ile Konformasyonel Değişimlendirmesi.
- 165 High-accuracy Automated Diagnosis of Parkinson's Disease. **2020**, 16, 688-694 4
- 164 The transcription factor BCL11A defines a distinctive subset of dopamine neurons in the developing and adult midbrain.
- 163 Co-editing PINK1 and DJ-1 genes via AAV-delivered CRISPR/Cas9 system in adult monkey brains elicits classic Parkinsonian phenotypes.
- 162 Fibrillar α -Synuclein induces neurotoxic astrocyte activation via RIP kinase signaling and NF- κ B.
- 161 Chronic Methamphetamine Increases Alpha-Synuclein Protein Levels in the Striatum and Hippocampus but not in the Cortex of Juvenile Mice. **2014**, 2, 3
- 160 Conditioning Against the Pathology of Parkinson's disease. **2018**, 1, 143-162 5
- 159 Kinetic monitoring of neuronal stress response to proteostasis dysfunction. **2021**, 118, 103682
- 158 Probiotic Enhancement of Antioxidant Capacity and Alterations of Gut Microbiota Composition in 6-Hydroxydopamine-Induced Parkinson's Disease Rats. **2021**, 10, 3
- 157 Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro. **2021**, 9, 188 3

156	βSynuclein-mediated neurodegeneration in Dementia with Lewy bodies: the pathobiology of a paradox. 2021 , 11, 196	1
155	Lewy Body Dementias: Controversies and Drug Development. 2021 , 1	0
154	Functional analyses of two novel LRRK2 pathogenic variants in familial Parkinson's disease.	
153	Proteostasis impairment and ER stress as a possible target to treat Parkinson's disease. 2021 , 2, 245-260	
152	Non-monotonic fibril surface occlusion by GFP tags from coarse-grained molecular simulations.. 2022 , 20, 309-321	0
151	Loss of Corticostriatal Mu-Opioid Receptors in βSynuclein Transgenic Mouse Brains.. 2022 , 12,	0
150	Olfactory Impairment and Neurodegenerative Disorders. 2021 , 145-158	
149	Controlled Activation of TRPV1 Channels on Microglia to Boost Their Autophagy for Clearance of Alpha-Synuclein and Enhance Therapy of Parkinson's Disease.. 2022 , e2108435	4
148	Methodology and Neuromarkers for Cetaceans' Brains.. 2022 , 9,	1
147	Dopaminergic imaging in degenerative parkinsonisms, an established clinical diagnostic tool.. 2021 ,	1
146	Neurogenetic traits outline vulnerability to cortical disruption in Parkinson's disease.. 2022 , 33, 102941	2
145	Sleep and circadian rhythms in Parkinson's disease and preclinical models.. 2022 , 17, 2	0
144	Therapeutics in the Pipeline Targeting -Synuclein for Parkinson's Disease.. 2022 , 74, 207-237	8
143	Metabolic Features of Brain Function with Relevance to Clinical Features of Alzheimer and Parkinson Diseases.. 2022 , 27,	1
142	A Matrigel-based 3D construct of SH-SY5Y cells models the βSynuclein pathologies of Parkinson's disease.. 2022 ,	1
141	Analysis of structure and dynamics of intrinsically disordered regions in proteins using solution NMR methods. 2022 , 535-550	
140	iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders.. 2022 , 29, 189-208	4
139	Modeling the cellular fate of alpha-synuclein aggregates: A pathway to pathology.. 2022 , 72, 171-177	0

138	Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers.. 2022,	1
137	Interaction of Alpha Synuclein and Microtubule Organization Is Linked to Impaired Neuritic Integrity in Parkinson's Patient-Derived Neuronal Cells.. 2022, 23,	2
136	Differentially targeted seeding reveals unique pathological alpha-synuclein propagation patterns.. 2021,	3
135	Neurodegenerative Diseases and the Gut Microbiota. 2022, 339-392	
134	Current Progress in the Development of Probes for Targeting β Synuclein Aggregates.. 2022,	0
133	Characterization of a Novel Monoclonal Antibody for Serine-129 Phosphorylated β Synuclein: A Potential Application for Clinical and Basic Research.. 2022, 13, 821792	1
132	Nanoscale Structural Analysis of a Lipid-Driven Aggregation of Insulin.. 2022, 2467-2473	6
131	The Role of NEDD4 E3 Ubiquitin-Protein Ligases in Parkinson's Disease.. 2022, 13,	2
130	A light-inducible protein clustering system for in vivo analysis of β Synuclein aggregation in Parkinson disease.. 2022, 20, e3001578	0
129	Regulation by Different Types of Chaperones of Amyloid Transformation of Proteins Involved in the Development of Neurodegenerative Diseases.. 2022, 23,	0
128	Biomarker of Neuroinflammation in Parkinson's Disease.. 2022, 23,	5
127	The roles of connectivity and neuronal phenotype in determining the pattern of β Synuclein pathology in Parkinson's disease.. 2022, 168, 105687	1
126	Brain-gut-microbiota axis in Parkinson's disease: a historical review and future perspective.. 2022,	3
125	β Synuclein Overexpression Increases Dopamine D2/3 Receptor Binding and Immune Activation in a Model of Early Parkinson's Disease.. 2021, 9,	1
124	A Critical Analysis of Quercetin as the Attractive Target for the Treatment of Parkinson's Disease. 2021,	0
123	Structure-based discovery of small molecule inhibitors of the autocatalytic proliferation of β Synuclein aggregates.	0
122	Differences in the Composition of Gut Microbiota between Patients with Parkinson's Disease and Healthy Controls: A Cohort Study. 2021, 10,	2
121	Potential Protein Blood-Based Biomarkers in Different Types of Dementia: A Therapeutic Overview.. 2022,	1

120 Image_1.tif. **2019**,

119 Image_2.TIF. **2019**,

118 Image_3.TIF. **2019**,

117 Image_4.TIF. **2019**,

116 Image_5.TIF. **2019**,

115 Data_Sheet_1.docx. **2020**,

114 Data_Sheet_1.pdf. **2018**,

113 Data_Sheet_2.docx. **2018**,

112 Data_Sheet_3.docx. **2018**,

111 Data_Sheet_1.pdf. **2019**,

110 Data_Sheet_1.doc. **2018**,

109 Table_1.docx. **2020**,

108 Image_1.JPEG. **2019**,

107 Image_2.JPEG. **2019**,

106 Image_3.JPEG. **2019**,

105 Image_4.JPEG. **2019**,

104 The Effects of Stress on Lewy Pathology in Dopamine Neurons.

103 Parkinson's Disease. **2022**, 82-93

102	The Importance Of Human Induced Pluripotent Stem Cells In Neurodegenerative Disorders.	
101	'Fly-ing' from rare to common neurodegenerative disease mechanisms.. 2022,	0
100	Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies. 2022, 13,	3
99	Types of Raman Scattering Techniques for Neurodegenerative Diseases. 2022, 39-57	
98	Baseline Cerebrospinal Fluid β Synuclein in Parkinson's Disease Is Associated with Disease Progression and Cognitive Decline. 2022, 12, 1259	
97	Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update.	0
96	Inflammatory Animal Models of Parkinson's Disease. 2022, 1-18	2
95	The Common Cellular Events in the Neurodegenerative Diseases and the Associated Role of Endoplasmic Reticulum Stress. 2022, 23, 5894	2
94	Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson's disease. 2022, 8,	3
93	Modeling Parkinson's disease-related symptoms in alpha-synuclein overexpressing mice.	0
92	The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability. 2022, 185, 2035-2056.e33	5
91	Plasticity of Membrane Binding by the Central Region of β Synuclein. 9,	1
90	Alpha-Synuclein and Parkinson's Disease Motor and Non-Motor Symptoms: What Is New?. 2022, 12, 904	
89	A review on pathology, mechanism, and therapy for cerebellum and tremor in Parkinson's disease. 2022, 8,	0
88	Disease modification in Parkinsonism: obstacles and ways forward.	2
87	Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson's Disease.	0
86	Tau and β Synuclein shape microtubule organization and microtubule-dependent transport in neuronal dendrites.	
85	β Synuclein induced cholesterol lowering increases tonic and reduces depolarization-evoked synaptic vesicle recycling and glutamate release. 2022, 8,	0

- 84 α Synucleinopathy exerts sex-dimorphic effects on the multipurpose DNA repair/redox protein APE1 in mice and humans. **2022**, 216, 102307 1
- 83 Neuronal identity defines α Synuclein and tau toxicity.
- 82 Cryo-EM structures of α Synuclein filaments from Parkinson's disease and dementia with Lewy bodies. 0
- 81 Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease. 1
- 80 Neuronal and glial characterization in the rostrocaudal axis of the human anterior olfactory nucleus: Involvement in Parkinson's disease. 16,
- 79 The role of inflammation in neurodegenerative diseases. **2023**, 403-421
- 78 Parkinson disease and other synucleinopathies. **2023**, 253-274
- 77 From clinical phenotype to proteinopathy: molecular neuroimaging in neurodegenerative dementias. **2022**, 80, 24-35
- 76 NXP031 prevents dopaminergic neuronal loss and oxidative damage in the AAV-WT- α Synuclein mouse model of Parkinson's disease. **2022**, 17, e0272085 1
- 75 G2019S LRRK2 Mutation Enhances MPP+-Induced Inflammation of Human Induced Pluripotent Stem Cells-Differentiated Dopaminergic Neurons. 16,
- 74 Gut microenvironmental changes as a potential trigger in Parkinson's disease through the gut-brain axis. **2022**, 29, 2
- 73 Advancing the Genetics of Lewy Body Disorders with Disease-Modifying Treatments in Mind. 2200011
- 72 Dynamic modelling and analysis of autophagy in the clearance of aggregated α Synuclein in Parkinson's disease.
- 71 A bibliometric analysis of neuroimaging biomarkers in Parkinson disease based on Web of Science. **2022**, 101, e30079
- 70 Gray Matter Volume Loss in Proposed Brain-First and Body-First Parkinson's Disease Subtypes. 0
- 69 The impact of α Synuclein aggregates on blood-brain barrier integrity in the presence of neurovascular unit cells.
- 68 Structural and functional abnormalities in Parkinson's disease based on voxel-based morphometry and resting-state functional magnetic resonance imaging. **2022**, 788, 136835
- 67 Subgrouping and structural brain connectivity of Parkinson's disease: Past studies and future directions. **2022**, 2, 100100 0

66	Human gut microbiota and Parkinson's disease. 2022,	1
65	Parkinson's disease-associated, sex-specific changes in DNA methylation at PARK7 (DJ-1), SLC17A6 (VGLUT2), PTPRN2 (IA-2) and NR4A2 (NURR1) in cortical neurons. 2022, 8,	1
64	Parkinson-causing mutations in LRRK2 impair the physiological tetramerization of endogenous α -synuclein in human neurons. 2022, 8,	1
63	Neuronal hyperactivity-induced oxidant stress promotes in vivo α -synuclein brain spreading. 2022, 8,	1
62	Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson's disease. 2022, 10,	1
61	Structures of α -synuclein filaments from human brains with Lewy pathology.	5
60	Lysosomal Pathogenesis of Parkinson's Disease: Insights From LRRK2 and GBA1 Rodent Models.	0
59	Relationship between Substantia Nigra Neuromelanin Imaging and Dual Alpha-Synuclein Labeling of Labial Minor in Salivary Glands in Isolated Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease. 2022, 13, 1715	1
58	REM sleep behavior and olfactory dysfunction: improving the utility and translation of animal models in the search for neuroprotective therapies for Parkinson's disease. 2022, 104897	0
57	Gut-oriented disease modifying therapy for Parkinson's disease. 2022,	0
56	Toothed Whales Have Black Neurons in the Blue Spot. 2022, 9, 525	0
55	Priming mesenchymal stem cells with α -synuclein enhances neuroprotective properties through induction of autophagy in Parkinsonian models. 2022, 13,	0
54	Axonal domain structure as a putative identifier of neuron-specific vulnerability to oxidative stress in cultured neurons. ENEURO.0139-22.2022	0
53	Microbiota- Brain-Gut-Axis Relevance to Parkinson's Disease: Potential Therapeutic Effects of Probiotics.. 2022, 28,	0
52	Combining NGN2 programming and dopaminergic patterning for a rapid and efficient generation of hiPSC-derived midbrain neurons. 2022, 12,	0
51	Modeling native and seeded Synuclein aggregation and related cellular dysfunctions in dopaminergic neurons derived by a new set of isogenic iPSC lines with SNCA multiplications. 2022, 13,	0
50	Association of Glial Activation and α -Synuclein Pathology in Parkinson's Disease.	1
49	A Conceptual Study on the Peripheral Clearance of Brain-Derived α -Synuclein in Humans. 2022, 1-8	0

48	SNCA Deletion Induced Aberrant Projection of Olfactory Sensory Neurons via NCK2-EphA4 Pathway.	0
47	D-FA-Based Trisubstituted Alkenes as Environmentally Sensitive Fluorescent Probes to Detect Lewy Pathologies.	0
46	Stem-Cell-Based Therapy: The Celestial Weapon against Neurological Disorders. 2022 , 11, 3476	1
45	Non-REM sleep electrophysiology in REM sleep behaviour disorder: A narrative mini-review. 2022 , 142, 104909	0
44	Association Between Decreased Srpk3 Expression and Increased Substantia Nigra Alpha-Synuclein Level in an MPTP-Induced Parkinson Disease Mouse Model.	0
43	Structure-Based Discovery of Small-Molecule Inhibitors of the Autocatalytic Proliferation of Synuclein Aggregates.	1
42	Nanotherapeutics a promising approach for treatment of Parkinson disease. 2022 ,	0
41	Mesoscale connections and gene expression empower whole-brain modeling of Synuclein spread, aggregation, and decay dynamics. 2022 , 41, 111631	0
40	Common and unique dysconnectivity profiles of dorsal and median raphe in Parkinson's disease.	0
39	Parkinson's Disease: Risk Factor Modification and Prevention. 2022 , 42, 626-638	0
38	Regulation of Lpha-Synuclein Gene (SNCA) by Epigenetic Modifier TET1 in Parkinson Disease. 2022 , 26, S85-93	0
37	Diffusion along perivascular spaces as marker for impairment of glymphatic system in Parkinson disease. 2022 , 8,	0
36	The hidden cell-to-cell trail of Synuclein aggregates. 2022 , 167930	0
35	Anti-Synuclein c-terminal antibodies block PFF uptake and accumulation of phospho-synuclein in preclinical models of Parkinson's disease. 2022 , 105969	1
34	The impact of Synuclein aggregates on blood-brain barrier integrity in the presence of neurovascular unit cells. 2022 ,	0
33	Gut-brain axis: Review on the association between Parkinson disease and plant lectins. 2022 , 9, 177-183	0
32	AAV-mediated Expression of a Novel Conformational Anti-Aggregated Synuclein Antibody Prolongs Survival in a Genetic Model of Synucleinopathies.	0
31	Hippocampal, basal ganglia and olfactory connectivity contribute to cognitive impairments in Parkinson disease.	0

30	Identification of mitophagy-associated proteins (MAPs) profile as potential plasma biomarkers of idiopathic Parkinson disease.	1
29	When the microbiome helps the brain-current evidence.	1
28	Administration of Neuropeptide Y into the rat nucleus accumbens shell, but not core, attenuates the motivational impairment from systemic dopamine receptor antagonism by Flupenthixol. 2023 , 137069	0
27	Risk of Parkinson disease associated with pesticide exposure and protection by probiotics. 2023 ,	1
26	Knocking out alpha-synuclein in melanoma cells downregulates L1CAM and decreases motility.	0
25	Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson Disease.	0
24	Multifaceted Pharmacological Potentials of Curcumin, Genistein, and Tanshinone IIA through Proteomic Approaches: An In-Depth Review. 2023 , 15, 249	1
23	Stimulus-responsive curcumin-based polydopamine nanoparticles for targeting Parkinson disease by modulating Synuclein aggregation and reactive oxygen species. 2023 , 141606	0
22	The c-Abl inhibitor IKT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson disease. 2023 , 15,	0
21	m 6 A mRNA methylation in human brain is disrupted in Lewy body disorders.	0
20	Interneuronal In Vivo Transfer of Synaptic Proteins. 2023 , 12, 569	0
19	Calcium/calmodulin-dependent serine protein kinase exacerbates mitochondrial calcium uniporter-related mitochondrial calcium overload by phosphorylating Synuclein in Parkinson disease. 2023 , 157, 106385	0
18	Gut-to-Brain Synuclein Transmission in Parkinson Disease: Evidence for Prion-like Mechanisms. 2023 , 24, 7205	0
17	Autoclave treatment fails to completely inactivate DLB alpha-synuclein seeding activity. 2023 , 34, 101446	0
16	D-685 Reverses Motor Deficits and Reduces Accumulation of Human Synuclein Protein in Two Different Parkinson Disease Animal Models. 2023 , 14, 885-896	0
15	Functionally Validating Evolutionary Conserved Risk Genes for Parkinson Disease in Drosophila melanogaster. 2023 , 14, 168	0
14	The reciprocal interactions between microglia and T cells in Parkinson disease: a double-edged sword. 2023 , 20,	1
13	Hallmarks of neurodegenerative diseases. 2023 , 186, 693-714	1

- 12 Common and distinct roles of amygdala subregional functional connectivity in non-motor symptoms of Parkinson's disease. **2023**, 9, ○
- 11 Small molecule-based fluorescent probes for the detection of β synuclein aggregation states. **2023**, 86, 129257 ○
- 10 Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo. ○
- 9 The small GTPase Rit2 modulates LRRK2 kinase activity, is required for lysosomal function and protects against alpha-synuclein neuropathology. **2023**, 9, ○
- 8 Molecular mechanisms of neuroprotective offerings by rosmarinic acid against neurodegenerative and other CNS pathologies. ○
- 7 Serum exosomes contain filamentous alpha-synuclein and facilitate the propagation of Parkinson's pathology. ○
- 6 Hippocampal subfield vulnerability to β synuclein pathology precedes neurodegeneration and cognitive dysfunction. ○
- 5 Dynamics of a model for the degradation mechanism of aggregated β synuclein in Parkinson's disease. 17, ○
- 4 Search for Molecular Biomarkers of Parkinson's Disease. New Tissues and Methods. **2023**, 23, 15-22 ○
- 3 LPS-induced mitochondrial dysfunction regulates innate immunity activation and β synuclein oligomerization in Parkinson's disease. **2023**, 63, 102714 ○
- 2 Concomitant protein pathogenesis in Parkinson's disease and perspective mechanisms. 15, ○
- 1 Post-inflammatory administration of N -acetylcysteine reduces inflammation and alters receptor levels in a cellular model of Parkinson's disease. ○